View as cardsView as table

Manipulating mitobiogenesis by targeting ME2

Fiscal Year Awarded:

2023

Principal Investigator:

David Scadden

Methods and applications of semi-permeable capsules with current application to high-throughput single cell multi-omics

Fiscal Year Awarded:

2023

Principal Investigator:

Allon Klein

A natural beta interferon-inducing therapeutic glycolipid from the microbiome that prevents and treats severe viral infection

Fiscal Year Awarded:

2022

Principal Investigator:

Dennis Kasper

A platform for transcriptome time-series in single cells with applications to hematopoietic stem cells

Fiscal Year Awarded:

2022

Principal Investigator:

Johan Paulsson

CNS drug delivery by identifying small molecule inhibitors of a newly identified key regulator of the blood brain barrier

Fiscal Year Awarded:

2022

Principal Investigator:

Chenghua Gu

Development of a novel monoclonal antibody that targets SARS-CoV-2 3a

Fiscal Year Awarded:

2022

Principal Investigator:

John Mekalanos

Enzyme prospecting for better diagnostics

Fiscal Year Awarded:

2022

Principal Investigator:

Michael Springer

Gene therapy for the treatment of Wolfram Syndrome II

Fiscal Year Awarded:

2022

Principal Investigator:

Amy Wagers

Novel biologics for cancer therapy

Fiscal Year Awarded:

2022

Principal Investigator:

George Church

Small molecule drugs for advanced cancer with ecDNA amplicons

Fiscal Year Awarded:

2022

Principal Investigator:

Timothy Mitchison